GOBBI, MARCO
 Distribuzione geografica
Continente #
EU - Europa 1.873
Totale 1.873
Nazione #
IT - Italia 1.873
Totale 1.873
Città #
Genova 958
Rapallo 464
Genoa 418
Bordighera 33
Totale 1.873
Nome #
Dexamethasone, oxaliplatin and cytarabine (R-DHAOx) as salvage and stem cells mobilizing therapy in relapsed/refractory diffuse large B cell lymphomas, file e268c4ca-bf91-a6b7-e053-3a05fe0adea1 768
A simple cytofluorimetric score may optimize testing for biallelic CEBPA mutations in patients with acute myeloid leukemia, file e268c4ca-ba16-a6b7-e053-3a05fe0adea1 242
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia., file e268c4c5-f3a8-a6b7-e053-3a05fe0adea1 213
High feasibility and antileukemic efficacy of fludarabine, cytarabine, and idarubicin (FLAI) induction followed by risk-oriented consolidation: A critical review of a 10-year, single-center experience in younger, non M3 AML patients, file e268c4ca-ca7c-a6b7-e053-3a05fe0adea1 137
Unmanipulated haploidentical transplants compared with other alternative donors and matched sibling grafts, file e268c4c6-b8e1-a6b7-e053-3a05fe0adea1 124
The new small tyrosine-kinase inhibitor ARQ531 targets acute myeloid leukemia cells by disrupting multiple tumor-addicted programs, file e268c4cb-4326-a6b7-e053-3a05fe0adea1 95
A blastic plasmacytoid dendritic cell neoplasm-like phenotype identifies a subgroup of npm1-mutated acute myeloid leukemia patients with worse prognosis, file e268c4ca-f531-a6b7-e053-3a05fe0adea1 89
Haploientical Transplants with Post-Transplant Cyclophosphamide for Relapsed or Refractory Hodgkin Lymphoma: The Role of Comorbidity Index and Pretransplant Positron Emission Tomography, file e268c4ca-6d1f-a6b7-e053-3a05fe0adea1 86
APO866 increases antitumor activity of cyclosporin - A by inducing mitochondrial and endoplasmic reticulum stress in leukemia cells, file e268c4cf-0b27-a6b7-e053-3a05fe0adea1 44
International randomized phase III study of elacytarabine versus investigator choice in patients with relapsed/refractory acute myeloid leukemia., file e268c4c6-b5d2-a6b7-e053-3a05fe0adea1 31
Nucleophosmin gene-based monitoring in de novo cytogenetically normal acute myeloid leukemia with nucleophosmin gene mutations: comparison with cytofluorimetric analysis and study of Wilms tumor gene 1 expression., file e268c4c6-cdf3-a6b7-e053-3a05fe0adea1 8
Depletion of SIRT6 enzymatic activity increases acute myeloid leukemia cells vulnerability to DNA-damaging agents, file e268c4ca-8944-a6b7-e053-3a05fe0adea1 7
Early minimal residual disease assessment after AML induction with fludarabine, cytarabine and idarubicin (FLAI) provides the most useful prognostic information, file e268c4ca-235e-a6b7-e053-3a05fe0adea1 6
Integrating post induction WT1 quantification and flow-cytometry results improves minimal residual disease stratification in acute myeloid leukemia., file e268c4c6-d183-a6b7-e053-3a05fe0adea1 5
Pegfilgrastim compared with filgrastim after autologous peripheral blood stem cell transplantation in patients with solid tumours and lymphomas., file e268c4c6-14d6-a6b7-e053-3a05fe0adea1 2
BeEAM (bendamustine, etoposide, cytarabine, melphalan) prior to autologous stem cell transplant is safe and effective for resistant/relapsed lymphoma patients., file e268c4c6-b82b-a6b7-e053-3a05fe0adea1 2
Intesive fludarabine-high dose cytarabine-idarubicin combination as induction therapy with risk-adapted consolidation may improve treatment efficacy in younger Acute Myeloid Leukemia (AML) patients: Rationales, evidences and future perspectives, file e268c4ca-93e7-a6b7-e053-3a05fe0adea1 2
Combined assessment of WT1 and BAALC gene expression at diagnosis may improve leukemia-free survival prediction in patients with myelodysplastic syndromes, file e268c4ca-a203-a6b7-e053-3a05fe0adea1 2
APO866 increases antitumor activity of cyclosporin - A by inducing mitochondrial and endoplasmic reticulum stress in leukemia cells, file e268c4cc-56b4-a6b7-e053-3a05fe0adea1 2
Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ)., file e268c4c5-f3a2-a6b7-e053-3a05fe0adea1 1
Effective in vivo induction of NKG2D ligands in acute myeloid leukaemias by all-trans-retinoic acid or sodium valproate., file e268c4c5-f3ad-a6b7-e053-3a05fe0adea1 1
Direct intrabone transplant of unrelated cord-blood cells in acute leukaemia: a phase I/II study, file e268c4c5-f9cb-a6b7-e053-3a05fe0adea1 1
Synergistic interactions between HDAC and sirtuin inhibitors in human leukemia cells., file e268c4c6-078d-a6b7-e053-3a05fe0adea1 1
Performance of serum (1,3)-ß-d-glucan screening for the diagnosis of invasive aspergillosis in neutropenic patients with haematological malignancies, file e268c4c9-acdf-a6b7-e053-3a05fe0adea1 1
Exploiting tumor vulnerabilities: NAD+-depleting agents combined with anti-tumor drugs as innovative strategy to treat hematological malignancies, file e268c4ca-6841-a6b7-e053-3a05fe0adea1 1
Age and comorbidities deeply impact on clinical outcome of patients with myelodysplastic syndromes, file e268c4ca-d2c5-a6b7-e053-3a05fe0adea1 1
Combining flow cytometry and WT1 assessment improves the prognostic value of pre-transplant minimal residual disease in acute myeloid leukemia, file e268c4ca-fd4d-a6b7-e053-3a05fe0adea1 1
Totale 1.873
Categoria #
all - tutte 3.493
article - articoli 3.493
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 6.986


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20192 0 0 0 0 0 0 0 0 0 0 1 1
2019/2020141 11 0 4 16 11 12 13 17 21 18 13 5
2020/2021239 10 6 17 11 4 26 23 20 26 29 31 36
2021/2022589 37 29 34 98 78 31 22 37 54 37 92 40
2022/2023572 31 43 83 44 57 75 35 27 43 45 52 37
2023/2024326 27 29 30 25 46 18 60 46 20 25 0 0
Totale 1.873